Sign inStart free

Health Care · Pharmaceutical Preparations

LRMR Larimar Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1374690116 filings
Russell 2000
Follow LRMR for alertsAsk AI about LRMR

LRMR at a glance

Larimar Therapeutics, Inc. (LRMR, SEC CIK 1374690) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on September 29, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Larimar Therapeutics, Inc. (LRMR) shares worth $68.3 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Hamilton Thomas Edward on July 6, 2026 of 50,000 shares at $3.34 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
25 funds
$68.3M · −1 vs prior quarter
Latest 8-K
Sep 29, 2026
Item 5.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Jun 30, 2026

Risk Factors

  • Newly added BLA risk triggered by June 2026 submission; FDA may refuse filing or deny accelerated approval
  • Most material regulatory update: fill-finish manufacturer received an FDA Form 483, requiring remediation before review
  • Safety-database adequacy remains subject to FDA review at BLA submission
  • Third-party site inspections could delay BLA submission or approval
  • Manufacturing continuity risk from dependence on third-party suppliers and qualification of an additional fill-finish source

AI summary of the LRMR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Sep 29, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • John B. Harlow appointed President and Chief Operating Officer effective September 29, 2026, adding commercial-stage biopharma leadership
  • $560,000 base salary, $35,000 signing bonus, and target annual bonus equal to 40% of salary
Filed Aug 4, 2026Full analysis →

Item 8.01: Other Events

  • Updated investor presentation posted August 4, 2026, signaling refreshed corporate and pipeline messaging
  • Exhibit 99.2 contains the substantive presentation for investors and analysts

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results and operational highlights announced for quarter ended June 30, 2026
  • Press release furnished as Exhibit 99.1, containing detailed financial and operational information

Item EX-99.1: Item EX-99.1

  • Q2 net loss $32.8M, or $0.30/share, versus $26.2M, reflecting accelerating development and commercialization spending
  • Cash, equivalents and marketable securities $156.3M at June 30, supporting runway into Q3 2027 without near-term financing indicated
Filed Jun 29, 2026Full analysis →

Item 8.01: Other Events

  • Rolling BLA submission initiated with FDA for accelerated approval of nomlabofusp
  • Regulatory milestone advances nomlabofusp toward potential approval for Friedreich’s ataxia

Item EX-99.1: Item EX-99.1

  • FDA alignment supports rolling BLA submission for accelerated approval, with first module filed and remaining modules expected in 2H 2026
  • Skin FXN exceeded 8.2 pg/µg in 100% of participants at 12 and 18 months, supporting FXN as a potential surrogate endpoint

AI summaries of LRMR 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LRMR

Don't miss the next LRMR filing

  • Alerts as it files. A push when LRMR files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LRMR, by share count.
  • Ask anything. An AI agent that reads every LRMR filing and answers with sources.
Follow LRMR for alertsAsk AI about LRMR
Compare plans →

LRMR alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Harlow John B. Jr.ASep 29, 2026-
Harlow John B. Jr.ASep 29, 2026-
Hamilton Thomas EdwardBuyJul 6, 2026$3.34
Hamilton Thomas EdwardAMay 19, 2026-
SHERMAN JEFFREY WAMay 19, 2026-
LEFF JONATHAN SAMay 19, 2026-
Truitt JosephAMay 19, 2026-
Flynn James EAMay 19, 2026-
Insider trades across all companies →Which insider buys matter →

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$41.8M-$90.9M-$172.5M
Net Income-$36.9M-$80.6M-$165.7M
Balance Sheet
Total Assets$95.9M$200.2M$145.8M
Equity$81.7M$171.8M$78.1M
ROE-45.2%-46.9%-212.2%
Per Share
EPS$-0.84$-1.32-
Cash Flow
Operating CF-$33.5M-$70.8M-$113.2M
CapEx$164K$515K$91K

Source: XBRL data in Larimar Therapeutics, Inc. (LRMR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q2 2026

Aggregate LRMR share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LRMR shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q2 202625$68.3M
Q1 202626$83.8M
Q4 202524$70.7M
Q3 202525$60.8M
Q2 202524$42.8M
Q1 202519$22.0M
Q4 202415$20.8M
Q3 202415$24.5M
Position changes: Q1 2026 → Q2 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 173 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LRMR filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Oct 1, 2026--
8-KSep 29, 2026Analysis-
10-QAug 4, 2026Analysis
8-KAug 4, 2026Analysis-
4Jul 8, 2026--
8-KJun 29, 2026Analysis-
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
4May 20, 2026-
8-KMay 19, 2026Analysis
8-KMay 14, 2026Analysis
10-QMay 14, 2026Analysis
10-KMar 19, 2026-
8-KMar 19, 2026Analysis-
8-KMar 9, 2026Analysis-
4Mar 2, 2026--
4Mar 2, 2026--
4Mar 2, 2026--
4Mar 2, 2026--
8-KFeb 27, 2026Analysis-
8-KFeb 24, 2026Analysis-
4Jan 27, 2026-

Related Health Care companies

All Health Care →

LRMR SEC filings: frequently asked questions

Which institutions hold LRMR stock?

As of June 30, 2026, the largest Larimar Therapeutics, Inc. (LRMR) holders among the 13F filers tracked by SignalX were BlackRock ($17.3 million), Vanguard Capital Management LLC ($9.1 million), AQR Capital Management ($7.2 million), Goldman Sachs Group ($5.3 million), Citadel Advisors LLC ($4.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did LRMR report in its latest 8-K?

Larimar Therapeutics, Inc. (LRMR) filed an 8-K on September 29, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). John B. Harlow appointed President and Chief Operating Officer effective September 29, 2026, adding commercial-stage biopharma leadership.

What are the latest LRMR SEC filings?

Larimar Therapeutics, Inc. (LRMR) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on September 29, 2026 and a Form 4 insider filing on October 1, 2026.

What is LRMR's SEC CIK number?

Larimar Therapeutics, Inc. (LRMR)'s SEC Central Index Key (CIK) is 1374690. EDGAR lists every LRMR filing under that number.

Ask anything about LRMR

The research agent reads LRMR's filings, financials, insider trades and 13F holders, then answers with sources.

Start free